Q3

Isofol Medical AB (publ) publishes interim report, January–September 2023

GOTHENBURG, Sweden, November 10, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–September 2023 is now available, in Swedish, on the company’s website, www.isofolmedical.com. The information in the press release is intended for investors. Third quarter, July – September 2023 Net revenue amounted to TSEK 0 […]

Isofol Medical AB (publ) publishes interim report, January–September 2023 Read More »

Isofol Medical AB (publ) publishes interim report, January–September 2022

GOTHENBURG, Sweden, November 11, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–September 2022 is now available on the company’s website, www.isofolmedical.com. The information in the press release is intended for investors. Third quarter, July – September 2022 Net revenue amounted to TSEK 2,907 (5,154) and

Isofol Medical AB (publ) publishes interim report, January–September 2022 Read More »

Isofol Medical AB (publ) publishes interim report for January – September 2021

GOTHENBURG, Sweden, November 11, 2021 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January – September 2021 is now available on the company’s website, www.isofolmedical.com. Third quarter, July –September 2021 Net revenue amounted to TSEK 5,154 (18,439) and other revenue to TSEK 0 (0) The result for

Isofol Medical AB (publ) publishes interim report for January – September 2021 Read More »

Scroll to Top